Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
125.78
-0.67 (-0.53%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
68
69
Next >
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
January 22, 2024
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns.
Via
InvestorPlace
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
January 20, 2024
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech...
Via
Talk Markets
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
January 19, 2024
2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Smart Money Is Betting Big In MRK Options
January 10, 2024
Via
Benzinga
Peering Into Merck & Co's Recent Short Interest
January 10, 2024
Via
Benzinga
Demystifying Merck & Co: Insights From 9 Analyst Reviews
January 09, 2024
Via
Benzinga
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
January 19, 2024
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups.
Via
Benzinga
Exposures
Product Safety
Why Is Cancer Focused Adagene Stock Plummeting Today?
January 17, 2024
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in...
Via
Benzinga
The 3 Best Dividend Growth Stocks to Buy in January 2024
January 17, 2024
These are the best dividend growth stocks to buy as they represent companies with healthy free cash flow upside visibility.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
January 16, 2024
FDA approves Merck's Keytruda for advanced cervical cancer. Keytruda plus chemoradiotherapy shows a 41% improvement in progression-free survival.
Via
Benzinga
Exposures
Product Safety
7 Healthcare Stocks Taking Medicine to the Next Level
January 14, 2024
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider.
Via
InvestorPlace
These 9 Stocks Are Running To Start 2024
January 14, 2024
The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
The 3 Best Blue-Chip Stocks to Buy in January 2024
January 10, 2024
With a history of consistent shareholder returns, the best blue-chip stocks will reward patient investors in 2024.
Via
InvestorPlace
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...
Via
Benzinga
Exposures
COVID-19
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
January 08, 2024
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Via
Benzinga
Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics
January 08, 2024
Via
Benzinga
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
January 08, 2024
The year's biggest medical conference kicked off with a melee of buyout news.
Via
Investor's Business Daily
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
January 08, 2024
Shares shot 7% higher in the first week of 2024 as excitement grows for its late-stage pipeline.
Via
Investor's Business Daily
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
January 08, 2024
Harpoon Therapeutics stock is rocketing higher on Monday as HARP investors react to Merck acquiring the company for $23 per share.
Via
InvestorPlace
Why Is Cancer Focused Harpoon Therapeutics Stock Shooting Higher Today?
January 08, 2024
Merck & Co Inc (NYSE: MRK) is reportedly negotiating to purchase cancer drugmaker Harpoon Therapeutics Inc (NASDAQ:
Via
Benzinga
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
January 08, 2024
These four names span different sectors, but all underperformed in 2023. Is it time to be a contrarian and pick up bargains on the discount aisle?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Wall Street's Top 10 Stock Calls This Week - Saturday, Jan. 6
January 06, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 2-5.
Via
Talk Markets
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Healthcare Champions Kick Off 2024
January 05, 2024
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly...
Via
Benzinga
Exposures
COVID-19
Dry January Investing: Trading Pints For Portfolio Growth
January 05, 2024
Around 15% of Americans said they were planning to participate in Dry January — a month of abstinence from alcohol — according to a survey.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
68
69
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.